Data governance foundations for AI in regulated quality systems Data governance foundations for AI in regulated quality systems Regulatory Affairs Context In the evolving landscape of pharmaceutical and biotechnology sectors, the integration of Artificial Intelligence (AI) into quality systems necessitates a robust framework for data governance, particularly regarding compliance with regulations such as 21 CFR Part 11 in the US and Annex 11 in the EU. Regulatory Affairs (RA) professionals must prioritize data integrity, validation, and compliance as they navigate the complexities of AI technologies in regulated environments. The advent of AI in quality systems offers significant potential for enhancing…

Validating AI enabled GxP systems under 21 CFR Part 11 and Annex 11 Validating AI Enabled GxP Systems under 21 CFR Part 11 and Annex 11 As the integration of artificial intelligence (AI) within Good Practice (GxP) systems becomes increasingly prevalent in the pharmaceutical and biotech industries, the demands for regulatory compliance have evolved. Regulatory Affairs (RA) professionals must navigate the complexities of validating AI-driven systems to ensure adherence to critical regulations such as 21 CFR Part 11 and Annex 11. This article serves as a comprehensive manual to guide regulatory professionals through the relevant regulations, guidelines, and agency expectations…

Audit Trail and Data Integrity Expectations for AI Quality Platforms Audit Trail and Data Integrity Expectations for AI Quality Platforms In the rapidly evolving landscape of pharmaceutical and biotechnology industries, the incorporation of Artificial Intelligence (AI) into quality systems presents various regulatory challenges. Understanding the intricacies of data governance associated with AI technologies, particularly concerning 21 CFR Part 11 compliance, is critical for regulatory affairs professionals. This manual aims to provide a comprehensive exploration of relevant regulations, guidelines, and agency expectations pertaining to audit trails and data integrity when utilizing AI quality platforms. Context The integration of AI in quality…

Model lifecycle management and version control for GxP AI tools Model lifecycle management and version control for GxP AI tools Context The integration of Artificial Intelligence (AI) in Good Automated Manufacturing Practice (GxP) environments has paved the way for enhanced data governance and improved quality outcomes. To ensure adherence to regulatory standards, especially within the frameworks of 21 CFR Part 11, organizations must focus on establishing a robust model lifecycle management and version control process. This article serves as a comprehensive guide for regulatory affairs professionals navigating the complexities of AI validation and compliance in the pharmaceutical and biotech sectors….

Building a validation master plan for AI and ML applications in QA Building a Validation Master Plan for AI and ML Applications in QA Context As artificial intelligence (AI) and machine learning (ML) technologies become increasingly integrated into quality assurance (QA) processes within pharmaceutical and biotech industries, regulatory affairs professionals must ensure these technologies comply with established regulations. Particularly, the guidance surrounding data governance, validation, and compliance with 21 CFR Part 11 is critical to ensure data integrity and reliability. This article will serve as a regulatory explainer manual that details the necessary framework for developing a robust validation master…

Case Studies of Data Governance Gaps that Undermined AI Initiatives Case Studies of Data Governance Gaps that Undermined AI Initiatives In today’s regulatory landscape, the integration of Artificial Intelligence (AI) systems in the pharmaceutical and biotechnology sectors presents unique challenges. Effective data governance is essential for ensuring compliance with regulatory mandates, particularly with respect to 21 CFR Part 11 in the United States, EU Annex 11, and device software regulations in the UK. This article outlines the critical link between data governance, AI validation, and compliance, illustrating case studies where lapses have undermined AI initiatives. Context The adoption of AI…

Designing Metadata Standards and Data Catalogs for AI Ready Quality Data Designing Metadata Standards and Data Catalogs for AI Ready Quality Data This regulatory explainer manual provides a comprehensive guide on the intersection of artificial intelligence (AI), data governance, and regulatory compliance specifically within the frameworks of 21 CFR Part 11 in the US, and similar regulations in the EU and UK. Designed for regulatory affairs professionals, this article elaborates on the necessary components for establishing robust metadata standards and data catalogs that ensure high-quality, compliant data in AI enabled environments. Regulatory Affairs Context As the pharmaceutical and biotechnology industries…

Managing Training, Test and Production Datasets Under Part 11 Controls Managing Training, Test and Production Datasets Under Part 11 Controls Regulatory Context In the rapidly evolving landscape of pharmaceuticals and biotechnology, artificial intelligence (AI) plays a pivotal role in quality systems. The Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the EU have established stringent regulations and guidelines on data governance, particularly concerning electronic records and signatures as outlined in 21 CFR Part 11. Compliance with these regulations is critical for ensuring the integrity and reliability of AI systems used throughout the…

How to document AI models and validation in CSV deliverables How to document AI models and validation in CSV deliverables Context As artificial intelligence (AI) technologies continue to permeate the pharmaceutical and biotech industries, the need for robust data governance has never been more critical. The integration of AI into Quality Systems mandates compliance with various regulatory standards, most notably the U.S. Food and Drug Administration (FDA) guidelines outlined in 21 CFR Part 11, the European Medicines Agency (EMA) requirements, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) directives. This article aims to serve as a regulatory explainer…

Supplier assessments and audits focused on AI data integrity controls Supplier assessments and audits focused on AI data integrity controls Regulatory Affairs Context In the evolving landscape of pharmaceutical and biotech sectors, the integration of Artificial Intelligence (AI) into quality systems presents unique challenges and opportunities. The regulatory framework governing these technologies, particularly in relation to data governance, validation, and compliance under 21 CFR Part 11, is critical for safeguarding data integrity and ensuring patient safety. Regulatory agencies such as the FDA, EMA, and MHRA have established guidelines that must be adhered to when integrating AI into quality assurance (QA)…